Antagonists of PD-1 and PD-L1 in Cancer Treatment.

Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell (2015) 5.10

Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer (2016) 2.19

The interplay of immunotherapy and chemotherapy: harnessing potential synergies. Cancer Immunol Res (2015) 1.04

High-Resolution PET Imaging with Therapeutic Antibody-based PD-1/PD-L1 Checkpoint Tracers. Theranostics (2016) 1.03

Tumor Regression and Allograft Rejection after Administration of Anti-PD-1. N Engl J Med (2016) 1.02

A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors. Oncotarget (2016) 0.97

PD-1/PD-L1 blockade in cancer treatment: perspectives and issues. Int J Clin Oncol (2016) 0.95

Immune Evasion Strategies of Glioblastoma. Front Surg (2016) 0.88

The immune microenvironment of breast ductal carcinoma in situ. Mod Pathol (2016) 0.85

Cancer immunoprevention. Curr Opin Immunol (2016) 0.83

PD-L1 Detection in Tumors Using [(64)Cu]Atezolizumab with PET. Bioconjug Chem (2016) 0.83

High microsatellite instability (MSI-H) colorectal carcinoma: a brief review of predictive biomarkers in the era of personalized medicine. Fam Cancer (2016) 0.81

PD-L1, PD-L2 and PD-1 expression in metastatic melanoma: Correlation with tumor-infiltrating immune cells and clinical outcome. Oncoimmunology (2016) 0.81

Targeting Stromal-Cancer Cell Crosstalk Networks in Ovarian Cancer Treatment. Biomolecules (2016) 0.80

Combined adjuvants of poly(I:C) plus LAG-3-Ig improve antitumor effects of tumor-specific T cells, preventing their exhaustion. Cancer Sci (2016) 0.79

Implementing liquid biopsies into clinical decision making for cancer immunotherapy. Oncotarget (2017) 0.77

PD-L1 (CD274) copy number gain, expression, and immune cell infiltration as candidate predictors for response to immune checkpoint inhibitors in soft-tissue sarcoma. Oncoimmunology (2017) 0.76

Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early Time-Point FDG-PET/CT Imaging in Patients with Advanced Melanoma. J Nucl Med (2017) 0.76

It's TIME for a biomarker-driven approach to cancer immunotherapy. J Immunother Cancer (2016) 0.75

Growth and Metastasis of Intraocular Tumors in Aged Mice. Invest Ophthalmol Vis Sci (2016) 0.75

Anti-Bovine Programmed Death-1 Rat-Bovine Chimeric Antibody for Immunotherapy of Bovine Leukemia Virus Infection in Cattle. Front Immunol (2017) 0.75

Radiotherapy and Immune Checkpoint Blockade for Melanoma: A Promising Combinatorial Strategy in Need of Further Investigation. Cancer J (2017) 0.75

Chordoma: The Quest for Better Treatment Options. Oncol Ther (2016) 0.75

Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade. J Immunother Cancer (2017) 0.75

Chimeric Antigen Receptor (CAR) T Cell Therapy for Malignant Pleural Mesothelioma (MPM). Cancers (Basel) (2017) 0.75

Mini-review of conventional and hypofractionated radiation therapy combined with immunotherapy for non-small cell lung cancer. Transl Lung Cancer Res (2017) 0.75

Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma. Curr Treat Options Oncol (2017) 0.75

Tumor cell-derived lactate induces TAZ-dependent upregulation of PD-L1 through GPR81 in human lung cancer cells. Oncogene (2017) 0.75

Imaging of programmed death ligand-1 (PD-L1): impact of protein concentration on distribution of anti-PD-L1 SPECT agent in an immunocompetent melanoma murine model. J Nucl Med (2017) 0.75

Pharmacokinetics, microscale distribution, and dosimetry of alpha-emitter-labeled anti-PD-L1 antibodies in an immune competent transgenic breast cancer model. EJNMMI Res (2017) 0.75

[Personalized oncology]. Radiologe (2017) 0.75

Targeted therapies for gastric cancer: failures and hopes from clinical trials. Oncotarget (2017) 0.75

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24

Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 29.75

The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 24.94

Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med (2013) 18.08

Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med (2013) 17.53

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol (2010) 17.13

Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med (2014) 16.83

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med (2003) 16.62

Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med (2012) 13.12

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature (2014) 12.00

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature (2014) 10.49

PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature (2014) 10.39

Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med (2014) 10.38

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med (2014) 10.10

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol (2014) 9.86

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet (2014) 8.63

Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res (2014) 8.11

Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A (2007) 7.49

Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med (2006) 7.10

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol (2014) 5.89

Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol (2013) 5.67

Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood (2010) 4.35

Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res (2011) 3.81

Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol (2014) 3.80

Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res (2012) 3.68

The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov (2014) 3.32

Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol (2012) 3.28

Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res (2013) 2.81

Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. J Clin Oncol (2014) 2.78

Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin Oncol (2013) 2.70

Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat (2014) 2.61

Tumor-expressed B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma. Clin Cancer Res (2009) 2.04

The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat (2013) 1.84

Identification and management of toxicities from immune checkpoint-blocking drugs. Oncology (Williston Park) (2014) 1.05

Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade. Expert Rev Anticancer Ther (2012) 1.03

Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma. Clin Cancer Res (2014) 1.01

Mapping the immunosuppressive environment in uterine tumors: implications for immunotherapy. Cancer Immunol Immunother (2014) 0.92

Ten years of progress in renal cell carcinoma. J Natl Compr Canc Netw (2012) 0.89

High-dose interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma: still the standard. Oncology (Williston Park) (2011) 0.79